High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients

BACKGROUND/AIMS: Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gut Liver
Main Authors: Pellicelli, Adriano, Messina, Vincenzo, Giannelli, Valerio, Distefano, Marco, Palitti, Valeria Pace, Vignally, Pascal, Tarquini, Pierluigi, Izzi, Antonio, Moretti, Alessandra, Babudieri, Sergio, Dell’Isola, Serena, Marignani, Massimo, Scifo, Gaetano, Iovinella, Vincenzo, Cariti, Giuseppe, Pompili, Maurizio, Candilo, Francesco Di, Fontanella, Luca, Ettorre, Giuseppe M., Vennarecci, Giovanni, Ippolito, Antonio Massimo, Barbarini, Giorgio
Formato: Artigo
Idioma:Inglês
Publicado em: Editorial Office of Gut and Liver 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7234881/
https://ncbi.nlm.nih.gov/pubmed/30970444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl18269
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados